|
|
|
22 May 2006 |
Diovan® the first blood pressure medication in a large-scale clinical trial to lower C-reactive protein, an important marker of inflammation
|
|
22 May 2006 |
Researchers Report Results for 28-day Phase II Study of VX-950 in Combination with Pegylated Interferon and Ribavirin in Hepatitis C Patients
|
|
22 May 2006 |
ViroPharma Announces Presentation of HCV-796 Phase 1b Data at Digestive Disease Week
|
|
22 May 2006 |
New Study Demonstrates That AMITIZA(TM) (lubiprostone) May Help Improve Symptoms of Irritable Bowel Syndrome With Constipation
|
|
20 May 2006 |
Synthetic Blood Reaches First Half of Traumatic Brain Injury Trial
|
|
19 May 2006 |
Arena Pharmaceuticals Announces Achievement of Phase 2 Clinical Milestone Under Cardiovascular Disease Collaboration With Merck
|
|
19 May 2006 |
Bristol-Myers Squibb Announces Discontinuation of Development of Muraglitazar, an Investigational Oral Treatment for Type 2 Diabetes
|
|
18 May 2006 |
deCODE Initiates Phase III Trial for DG031 for the Prevention of Heart Attack
|
|
18 May 2006 |
Teva Announces FDA Grants Approval of Azilect® (Rasagiline) for Parkinson's Disease
|
|
18 May 2006 |
Amarin Acquires Parkinson's Disease Drug Candidate
|
|
18 May 2006 |
Independent Data Monitoring Board Recommends Expedited Interim Analysis of Overall Survival Data for Satraplatin Phase 3 Trial
|
|
17 May 2006 |
Carna Biosciences and Enamine Sign Collaboration
|
|
17 May 2006 |
Arginox Pharmaceuticals Reaches 50 Percent Enrollment Target in Its Pivotal Phase 3 Study of Tilarginine Acetate Injection in Cardiogenic Shock
|
|
17 May 2006 |
Rigel Announces Pfizer Selection of R343, a Syk Kinase Inhibitor, for Advanced Preclinical Development in Allergic Asthma
|
|
17 May 2006 |
Targacept Announces Positive Phase II Results for TC-1734 (AZD3480) in Memory Impaired Older Subjects
|
|
17 May 2006 |
Vertex Pharmaceuticals Initiates Phase I Development for VX-770 in Cystic Fibrosis
|
|
17 May 2006 |
Phase III Community-Acquired Pneumonia Study Opens for Basilea’s Novel Broad-spectrum anti-MRSA Antibiotic Ceftobiprole to Broaden Indications
|
|
17 May 2006 |
New data demonstrates efficacy of Rasilez as a potentially innovative oral direct renin inhibitor for treatment of high blood pressure
|
|
17 May 2006 |
Novartis announces first Phase III Exforge data, shows strong efficacy as new high blood pressure treatment with dual mechanisms of action
|
|
17 May 2006 |
Basilea Completes Patient Recruitment of Alitretinoin Pivotal Phase III Study in Patients with Severe Chronic Hand Dermatitis
|
|
17 May 2006 |
NicOx and Ferrer Select Candidate for Development In Dermatology Collaboration
|
|
17 May 2006 |
Valeant Receives FDA Marketing Approval for Cannabinoid Cesamet(TM) (CII)
|
|
17 May 2006 |
ABILIFY(R) (Aripiprazole) Demonstrated Efficacy as Maintenance Therapy In Adults with Bipolar I Disorder Following Treatment for a Recent Manic or Mixed Episode
|
|
17 May 2006 |
MIGENIX Receives Approval for MX-3253 Phase II Combination Viral Kinetics Study in HCV Treatment-Naive Patients
|
|
17 May 2006 |
Theravance Announces Enrollment of Last Patient in Phase 3 Complicated Skin and Skin Structure Infections Clinical Program with Investigational Antibiotic, Telavancin
|
|
17 May 2006 |
Neurocrine Receives Approvable Letter for indiplon Capsules and Non-Approvable for indiplon Tablets for the Treatment of Insomnia
|
|
17 May 2006 |
Nymox Reports Positive New Efficacy Data for Benign Prostatic Hyperplasia Drug
|
|
17 May 2006 |
Manhattan Pharmaceuticals Receives SwissMedic's Approval To Commence Phase IIa Trial With OE, Its Oral Obesity Drug Candidate
|
|
17 May 2006 |
Marshall Edwards achieves special protocol assessment and agreement with the FDA
|
|
17 May 2006 |
PhytoMedical’s BDC-O3 Compound Shown to Elevate HDL, “Good” Cholesterol
|
|
16 May 2006 |
Hedgehog Antagonist Data Presented at Australasian College of Dermatologists Scientific Meeting
|
|
16 May 2006 |
GlaxoSmithKline and Vertex Pharmaceuticals Announce Preliminary 48-Week Results from Head-to-Head Clinical Study of HIV Protease Inhibitors Lexiva (Telzir) and Kaletra in Treatment-naïve Patients with HIV
|
|
16 May 2006 |
GPC Biotech Announces Start of Phase 1 Trial Evaluating Satraplatin plus Xeloda® in Patients with Advanced Solid Tumors
|
|
16 May 2006 |
BioAlliance Pharma Starts Pivotal Phase III Clinical Trial in the US of Loramyc(R) Treatment for Oropharyngeal Candidiasis
|
|
16 May 2006 |
U.S. FDA Grants Orphan Drug Designation to OXiGENE's Lead Clinical Candidate, Combretastatin A4P (CA4P), for the Treatment of Ovarian Cancer; Award Marks Second Orphan Drug Indication for CA4P
|
|
16 May 2006 |
Eisai Files Application with the MHRA for New Aricept(R) Indication: Severe Alzheimer's Disease
|
|
16 May 2006 |
Pixantrone Produces High Rate (77 percent) of Complete Tumor Disappearance in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
|
|
16 May 2006 |
Taro to Begin Dose Escalation Study of T2000 in Canada to Evaluate Efficacy in Essential Tremor
|
|
16 May 2006 |
European Commission Approves Keppra(R) for Use as Adjunctive Therapy in the Treatment of Myoclonic Seizures in Patients with Juvenile Myoclonic Epilepsy
|
|
16 May 2006 |
TorreyPines Therapeutics Completes Phase I Clinical Trial for Tezampanel (NGX424), a First-in-Class Compound for Acute Migraine
|
|
16 May 2006 |
Axonyx Announces Completion Of The Multiple-Dose Phase I Study Of Posiphen
|
|
15 May 2006 |
New Prescription Pain Treatment Completes European Mutual Recognition Procedure
|
|
15 May 2006 |
Sosei Discontinues Development Of SOU-001
|
|
15 May 2006 |
Advancis Pharmaceutical Receives FDA Approval Letter for New Strengths of Keflex
|
|
15 May 2006 |
EntreMed Initiates Combination Phase 2 Clinical Trial With Panzem(R) NCD in Carcinoid Cancer
|
|
15 May 2006 |
Geron And TA Therapeutics Announce Presentation Of New Data Supporting Utility Of Their Small Molecule Telomerase Activator TAT0002
|
|
15 May 2006 |
Nereus Pharmaceuticals Initiates Phase I Clinical Trial for Anti-Cancer Proteasome Inhibitor
|
|
15 May 2006 |
GTx, Inc. Initiates Phase II Clinical Trial of Ostarine, a First-in-Class Drug
|
|
13 May 2006 |
PTC Therapeutics Initiates Phase 1a Clinical Trial of PTC299
|
|
12 May 2006 |
Pfizer's Smoking Cessation Medicine Chantix™ (Varenicline) Receives FDA Approval
|
| |
|
Results 5051 - 5100 of 5705 |
